Comparison of PAX6 and PAX8 as Immunohistochemical Markers for Pancreatic Neuroendocrine Tumors
- PDF / 1,717,958 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 44 Downloads / 225 Views
Comparison of PAX6 and PAX8 as Immunohistochemical Markers for Pancreatic Neuroendocrine Tumors Jin-Ping Lai & Richard B. Mertens & James Mirocha & Jamie Koo & Mariza Venturina & Fai Chung & Allen B. Mendez & Melissa Kahn & Deepti Dhall
Published online: 30 November 2014 # Springer Science+Business Media New York 2014
Abstract To compare the utility of PAX6 and PAX8 as immunohistochemical markers for neuroendocrine tumors (NETs) of pancreatic origin, we performed PAX6 and PAX8 immunostains on 178 NETs, including 110 primary NETs (26 pancreatic, 10 gastric, 12 duodenal, 22 jejuno-ileal, 10 rectal, 30 pulmonary) and 68 NETs metastatic to the liver (24 pancreatic, 1 duodenal, 37 jejuno-ileal, 1 rectal, 5 pulmonary). Among primary NETs, PAX6 and PAX8 were positive in 65 % (17/26) and 73 % (19/ 26) of pancreatic, 0 % (0/10) and 10 % (1/10) of gastric, 92 % (11/12) and 92 % (11/12) of duodenal, 0 % (0/22) and 0 % (0/22) of jejuno-ileal, 90 % (9/10) and 80 % (8/10) of rectal, and 0 % (0/30) and 23 % (7/30) of pulmonary NETs, respectively. PAX6 and PAX8 positivity was seen in 46 % (11/24) and 50 % (12/24) of metastatic pancreatic NETs to the liver, respectively. None of the nonpancreatic NETs metastatic to the liver were immunoreactive for either PAX6 or PAX8. PAX6 showed a slightly but statistically significant higher specificity for pancreatic NETs than did PAX8 (P=0.039), while the sensitivities were similar (P=0.51). PAX6 had the additional advantages over PAX8 of not exhibiting nonspecific cytoplasmic staining of tumor cells and only infrequently staining background lymphocytes. Since rectal NETs rarely present with metastatic disease, positive staining of a metastatic NET of unknown primary origin for PAX6 J.
Data Loading...
